Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 4027.41% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 85.23M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 891.29, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 17.18M shares, decreasing 27.94% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 4.38K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.08.